Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionMercer Global Advisors Inc /adv
Latest Disclosed Ownership22,762 shares
Latest Disclosed Value $ 10,164,198
Mercer Global Advisors Inc /adv reports 4.45% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Mercer Global Advisors Inc /adv filed a 13F-HR form disclosing ownership of 22,762 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $10,164,143 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 23,822 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -4.45% during the quarter. The current value of the position is $10,170,744 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 22,762 -1,060 -4.45 10,164 13.11 0.0150
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,822 5,038 26.82 8,986 22.16 0.0137
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,784 261 1.41 7,357 -10.79 0.0123
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,523 3,462 22.99 8,247 12.94 0.0168
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,061 1,053 7.52 7,302 29.45 0.0167
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,008 -1,543 -9.92 5,641 -22.72 0.0138
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,551 -952 -5.77 7,298 -5.17 0.0171
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,503 3,106 23.18 7,697 153,820.00 0.0210
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,397 -1,119 -7.71 6 0.00 0.0159
2024-02-15 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,516 2,789 23.78 6 25.00 0.0178
2023-11-15 2023-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 11,727 713 6.47 4 33.33 0.0155
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,727 713 4 0.0155
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,014 899 8.89 4 0.00 0.0154
2023-05-16 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,115 1,821 21.96 3 50.00 0.0145
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,294 170 2.09 2 -99.91 0.0120
2022-11-15 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,124 -835 -9.32 2,352 -6.85 0.0140
2022-08-10 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,959 -1,127 -11.17 2,525 -4.07 0.0155
2022-05-10 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,086 613 6.47 2,632 26.54 0.0155
2022-02-04 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,473 2,251 31.17 2,080 58.78 0.0128
2021-11-10 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,222 814 12.70 1,310 1.39 0.0092
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,408 -11,397 -64.01 1,292 -66.24 0.0099
2021-08-10 2021-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 17,805 12,652 245.53 3,827 214.20 0.0348
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,688 -1,465 793 0.0076
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,153 -1,651 -24.27 1,218 -34.23 0.0152
2020-12-10 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,804 687 11.23 1,852 4.28 0.0279
2020-08-10 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,117 4,667 321.86 1,776 414.78 0.0322
2020-05-18 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,450 -47 -3.14 345 5.18 0.0076
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 1,497 -10 -0.66 328 28.63 0.0065
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 1,507 49 3.36 255 -4.49 0.0060
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS INC COM COM 92532F100 1,458 29 2.03 267 1.52 0.0071
2019-04-23 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS INC COM COM 92532F100 1,429 1,429 263 0.0095
2019-04-12 2019-03-31 13F VERTEX PHARMACEUTICALS I COM 92532F100 1,304 216 0.0115
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.